Response among all patients and in patient subsets
| . | All patients (N = 46) . | Rituximab refractory (n = 30) . | Refractory to last regimen (n = 29) . | Primary refractory (n = 15) . | POD24 (n = 26) . | Prior ASCT (n = 10) . | Prior LOT . | |
|---|---|---|---|---|---|---|---|---|
| ≤2 (n = 10) . | >2 (n = 36) . | |||||||
| ORR, n (%)∗ | 24 (52.2) | 13 (43.3) | 13 (44.8) | 5 (33.3) | 15 (57.7) | 9 (90.0) | 5 (50.0) | 19 (52.8) |
| CR | 14 (30.4) | 8 (26.7) | 7 (24.1) | 3 (20.0) | 9 (34.6) | 6 (60.0) | 2 (20.0) | 12 (33.3) |
| PR | 10 (21.7) | 5 (16.7) | 6 (20.7) | 2 (13.3) | 6 (23.1) | 3 (30.0) | 3 (30.0) | 7 (19.4) |
| SD, n (%) | 9 (19.6) | 7 (23.3) | 8 (27.6) | 3 (20.0) | 5 (19.2) | 0 | 2 (20.0) | 7 (19.4) |
| PD, n (%) | 9 (19.6) | 7 (23.3) | 7 (24.1) | 4 (26.7) | 3 (11.5) | 0 | 1 (10.0) | 8 (22.2) |
| NA, n (%)† | 4 (8.7) | 3 (10.0) | 1 (3.4) | 3 (20.0) | 3 (11.5) | 1 (10.0) | 2 (20.0) | 2 (5.6) |
| . | All patients (N = 46) . | Rituximab refractory (n = 30) . | Refractory to last regimen (n = 29) . | Primary refractory (n = 15) . | POD24 (n = 26) . | Prior ASCT (n = 10) . | Prior LOT . | |
|---|---|---|---|---|---|---|---|---|
| ≤2 (n = 10) . | >2 (n = 36) . | |||||||
| ORR, n (%)∗ | 24 (52.2) | 13 (43.3) | 13 (44.8) | 5 (33.3) | 15 (57.7) | 9 (90.0) | 5 (50.0) | 19 (52.8) |
| CR | 14 (30.4) | 8 (26.7) | 7 (24.1) | 3 (20.0) | 9 (34.6) | 6 (60.0) | 2 (20.0) | 12 (33.3) |
| PR | 10 (21.7) | 5 (16.7) | 6 (20.7) | 2 (13.3) | 6 (23.1) | 3 (30.0) | 3 (30.0) | 7 (19.4) |
| SD, n (%) | 9 (19.6) | 7 (23.3) | 8 (27.6) | 3 (20.0) | 5 (19.2) | 0 | 2 (20.0) | 7 (19.4) |
| PD, n (%) | 9 (19.6) | 7 (23.3) | 7 (24.1) | 4 (26.7) | 3 (11.5) | 0 | 1 (10.0) | 8 (22.2) |
| NA, n (%)† | 4 (8.7) | 3 (10.0) | 1 (3.4) | 3 (20.0) | 3 (11.5) | 1 (10.0) | 2 (20.0) | 2 (5.6) |